Pluristem
researches, develops and commercializes cell therapies for the treatment of inflammation, ischemia and hematological disorders... Read morePluristem
researches, develops and commercializes cell therapies for the treatment of inflammation, ischemia and hematological disorders... Read more
News
Feb 12, 2025
Owler
Pluristem Therapeutics, Inc.: Pluristem's revenue changed from $598K in Sep 2024 to $678K in Dec 2024
Feb 04, 2025
GlobeNewswire
Press Release: Pluristem : Pluri Secures Additional $3.5 Million Investment from Major Shareholder at Premium to Market, Bringing Total Recent Financings to $10 Million
Dec 19, 2024
GlobalNewswire
Press Release: Pluristem : Pluri Congratulates Mesoblast on FDA Approval of First Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft-Versus-Host Disease
Dec 04, 2024
Pluristem Youtube Channel
Pluristem posted a video "Coffeesai - Pluri's cell-based coffee subsidiary" on YOUTUBE
Nov 13, 2024
Owler
Pluristem Therapeutics, Inc.: Pluristem's revenue changed from $326K in Jun 2024 to $598K in Sep 2024
May 16, 2024
Pluristem Youtube Channel
Pluristem posted a video "Nasdaq interview with Pluri CEO Yaky Yanay on cell therapy for Acute Radiation Syndrome" on YOUTUBE
Apr 18, 2024
Pluristem Youtube Channel
Pluristem posted a video "CEO & President Yaky Yanay on Passive Income Investor - April 2024" on YOUTUBE
Mar 11, 2024
GlobalNewswire
Press Release: Pluristem : Pluri Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation
Mar 07, 2024
Pluristem Youtube Channel
Pluristem posted a video "CEO & President Yaky Yanay on Passive Income Investor" on YOUTUBE
Feb 14, 2024
Owler
Pluristem Therapeutics, Inc.: Pluristem's revenue changed from $519K in Sep 2023 to $622K in Dec 2023
Pluristem Competitors
1
2
3
4
5
6
7
8
9
10